Replimune Group Q3 EPS Estimate Lowered by Leerink Partnrs

Replimune Group, Inc. (NASDAQ:REPL) – Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings estimates for Replimune Group in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of ($0.71) for the quarter, down from their previous forecast of ($0.64). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07.

A number of other research analysts have also recently issued reports on REPL. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research report on Tuesday. Finally, JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.80.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $10.80 on Friday. Replimune Group has a 12 month low of $4.92 and a 12 month high of $12.97. The firm has a market capitalization of $738.94 million, a P/E ratio of -3.54 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18. The business has a fifty day simple moving average of $11.46 and a two-hundred day simple moving average of $9.54.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Nisa Investment Advisors LLC lifted its position in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the second quarter worth $57,000. Arizona State Retirement System purchased a new position in shares of Replimune Group in the second quarter worth $108,000. Quest Partners LLC lifted its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the third quarter valued at $133,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.